MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)
CANTON, Mich. (October 15, 2024) – MMS, a leading data and regulatory focused clinical research organization (CRO), today announced that it has been awarded bronze medal status by EcoVadis, demonstrating its commitment to environmental, social, and governance (ESG) initiatives. Bronze medal status is earned by organizations that are in the top 35th percentile globally when scored against criteria across a variety of environmental, ethical, social and sustainability factors.
The EcoVadis assessment evaluates 21 sustainability criteria across four core themes: Environment, Labor & Human Rights, Ethics and Sustainable Procurement. More than 130,000 companies across 175 countries globally have been rated by EcoVadis.
“MMS is proud of our recognized leadership position in ESG, which has been a strong element of our culture for more than 18 years in the pharmaceutical industry,” said MMS Chief Commercial Officer Ben Dudley. “At these times, ESG is the responsibility of any corporation and efforts require commitment and buy-in from global teams. At MMS, we are executing robust and holistic strategies across all the ESG domains, and our value-adding efforts have been recognized through the validated methodology employed by EcoVadis. We will continue to advance progress both within MMS and across our entire supply chain.”
This status reflects a 25 percent increase in positive scores for MMS from EcoVadis year-over-year.
EcoVadis’ business sustainability ratings are based on international sustainability standards, such as the Ten Principles of the UN Global Compact, the International Labor Organization (ILO) conventions, the Global Reporting Initiative (GRI) standards, and the ISO 26000 standard. The ratings provide an evidenced-based analysis on performance and an actionable roadmap for continuous improvement.
Pharmaceutical industry leaders demand sustainable CRO partners
According to the CPHI sustainability sentiment index, 95 percent of pharmaceutical and biotechnology executives recently shared that it is important to have visibility on their partners’ sustainability credentials and practices.
“This recognition by EcoVadis is yet another validation of the MMS’ mission to positively improve patient’s lives by delivering excellence in drug development and meaningfully contribute to our internal MMS as well as our Sponsors’ sustainability goals,” said Alan Nicolle, Vice President of Operational Business Strategy, MMS. “As the pharmaceutical industry increasingly prioritizes sustainability, MMS stands strong at the forefront of driving eco-conscious innovation across drug development, ensuring that together we can meet both business and environmental goals.”
Dudley added, “MMS is one of the few CROs that has been ISO certified since inception, and our dedication to deep processes, sustainability, and ethical practices remains integral to our global growth. From reducing environmental impact in trial designs to fostering a diverse, inclusive, and ethical workforce, we have always demonstrated our commitment, and we continue to set new standards for what it means to be a responsible CRO partner.”
Learn more about our commitment to the environment and our clients at https://mmsholdings.com/.
About MMS
MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating.
For more information, visit www.mmsholdings.com
Media Contact
Don F. McLean
dmclean1@mmsholdings.com